Haleon US Holdings LLC has received FDA approval for the expanded pediatric indication of Junior Strength Advil (ibuprofen), a reformulation of the generic product formerly known as Advil Junior Strength, with implications indicated for easing sore throats. This approval addresses a critical market gap for non-prescription dosing of ibuprofen designed for children and marks a significant strategic step in Haleon's US pediatric product pipeline.